Cognetivity Neurosciences Ltd - Ordinary Shares

Canadian Securities Exchange (CNSX) | Oct 16, 2019, 3:41 AM EDT

CGN:CNX $ 0.125
0.01 (8.6957%)
Day Low: 0.125
Day High: 0.135
Cognetivity Neurosciences Receives Milestone European & US Patent Approvals
Cognetivity Neurosciences Receives Milestone European & US Patent Approvals

Cognetivity Neurosciences Receives Milestone European & US Patent Approvals

Canada NewsWire

VANCOUVER, Sept. 17, 2018 /CNW/ - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN) (FWB:1UB) announced that it has received two key patent application approvals from the European and United States Patent Offices.

Both patents have been granted against Cognetivity's proprietary Integrated Cognitive Assessment (ICA), an artificial-intelligence (AI) system to assess mental health disorders in humans. The system's initial focus is on early diagnosis of dementia, in particular Alzheimer's Disease, by detection of the early stages of loss of cognitive performance associated with the disease.

Securing patent approvals in two of the largest future markets for Cognetivity's technology   supports the Company's documented growth strategy and paves the way for the company to selectively develop its market opportunities while it drives towards full commercialization over the coming months.

Cognetivity's CEO and Director, Dr. Sina Habibi said: "Securing patents in key markets for our technology is a major company milestone and something we've worked very hard to achieve. This protection of our unique and innovative technology puts us in a strong position as we move through the final stages of the regulatory process, finalize our clinical product and launch a commercial product within these territories."

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

For more information please visit –


 "Sina Habibi"                                               

Sina Habibi
Chief Executive Officer and Director


The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release

SOURCE Cognetivity Neurosciences Ltd

View original content:

Email:; For media enquiries contact: Josh Stanbury, Email: CNW Group 2018

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.